Mesenchymal stem cells for sensorineural hearing loss: Protocol for a systematic review of preclinical studies

Kevin T. Chorath, Matthew J. Willis, Nicolas Morton-Gonzaba, Walter J. Humann, Alvaro G Moreira

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background: Sensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patients. Preclinical animal studies have demonstrated that mesenchymal stem cells (MSCs) could be a promising new therapy for this condition. These findings have prompted investigators to begin human clinical trials to assess the safety and efficacy of MSCs for the treatment of SNHL. The objective of the proposed systematic review is to examine the efficacy of MSCs as a therapy for SNHL in animal models. Methods: We will include preclinical animal studies of SNHL in which MSCs are administered, and outcomes are compared against MSC-naïve controls. The primary outcome will include audiologic tests that are routinely used in experimental studies of hearing loss, such as auditory brainstem response (ABR) and distortion product otoacoustic emissions testing (DPOAE). Secondary outcomes will include histology, microscopy, gene protein expression, and behavioral responses of animals. Electronic searches of MEDLINE via PubMed, Scopus, ScienceDirect, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be performed. Search results will be screened independently and in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias and publication bias will be assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool and Funnel Plots/Egger's regression tests, respectively. Discussion: This systematic review will provide a summary of the efficacy of MSC therapy in animal models of SNHL, utilizing functional hearing assessment as a primary outcome. Findings from this review are important because they can elucidate research gaps that should be addressed in future preclinical studies and in turn can be translated into clinical studies.

Original languageEnglish (US)
Article number126
JournalSystematic Reviews
Volume8
Issue number1
DOIs
StatePublished - May 25 2019

Fingerprint

Sensorineural Hearing Loss
Mesenchymal Stromal Cells
Hearing Loss
Cell- and Tissue-Based Therapy
Hearing
Animal Models
Spiral Ganglion
Publication Bias
Brain Stem Auditory Evoked Potentials
Alopecia
Laboratory Animals
PubMed
MEDLINE
Microscopy
Histology
Nursing
Stem Cells
Therapeutics
Research Personnel
Clinical Trials

Keywords

  • Animal models
  • Mesenchymal stem cells
  • Preclinical
  • Risk of bias
  • Sensorineural hearing loss
  • Stem cells
  • Systematic reviews

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Mesenchymal stem cells for sensorineural hearing loss : Protocol for a systematic review of preclinical studies. / Chorath, Kevin T.; Willis, Matthew J.; Morton-Gonzaba, Nicolas; Humann, Walter J.; Moreira, Alvaro G.

In: Systematic Reviews, Vol. 8, No. 1, 126, 25.05.2019.

Research output: Contribution to journalReview article

Chorath, Kevin T. ; Willis, Matthew J. ; Morton-Gonzaba, Nicolas ; Humann, Walter J. ; Moreira, Alvaro G. / Mesenchymal stem cells for sensorineural hearing loss : Protocol for a systematic review of preclinical studies. In: Systematic Reviews. 2019 ; Vol. 8, No. 1.
@article{26f5573d6e7248a4a756f19acebeb5bf,
title = "Mesenchymal stem cells for sensorineural hearing loss: Protocol for a systematic review of preclinical studies",
abstract = "Background: Sensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patients. Preclinical animal studies have demonstrated that mesenchymal stem cells (MSCs) could be a promising new therapy for this condition. These findings have prompted investigators to begin human clinical trials to assess the safety and efficacy of MSCs for the treatment of SNHL. The objective of the proposed systematic review is to examine the efficacy of MSCs as a therapy for SNHL in animal models. Methods: We will include preclinical animal studies of SNHL in which MSCs are administered, and outcomes are compared against MSC-na{\"i}ve controls. The primary outcome will include audiologic tests that are routinely used in experimental studies of hearing loss, such as auditory brainstem response (ABR) and distortion product otoacoustic emissions testing (DPOAE). Secondary outcomes will include histology, microscopy, gene protein expression, and behavioral responses of animals. Electronic searches of MEDLINE via PubMed, Scopus, ScienceDirect, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be performed. Search results will be screened independently and in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias and publication bias will be assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool and Funnel Plots/Egger's regression tests, respectively. Discussion: This systematic review will provide a summary of the efficacy of MSC therapy in animal models of SNHL, utilizing functional hearing assessment as a primary outcome. Findings from this review are important because they can elucidate research gaps that should be addressed in future preclinical studies and in turn can be translated into clinical studies.",
keywords = "Animal models, Mesenchymal stem cells, Preclinical, Risk of bias, Sensorineural hearing loss, Stem cells, Systematic reviews",
author = "Chorath, {Kevin T.} and Willis, {Matthew J.} and Nicolas Morton-Gonzaba and Humann, {Walter J.} and Moreira, {Alvaro G}",
year = "2019",
month = "5",
day = "25",
doi = "10.1186/s13643-019-1015-7",
language = "English (US)",
volume = "8",
journal = "Systematic Reviews",
issn = "2046-4053",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Mesenchymal stem cells for sensorineural hearing loss

T2 - Protocol for a systematic review of preclinical studies

AU - Chorath, Kevin T.

AU - Willis, Matthew J.

AU - Morton-Gonzaba, Nicolas

AU - Humann, Walter J.

AU - Moreira, Alvaro G

PY - 2019/5/25

Y1 - 2019/5/25

N2 - Background: Sensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patients. Preclinical animal studies have demonstrated that mesenchymal stem cells (MSCs) could be a promising new therapy for this condition. These findings have prompted investigators to begin human clinical trials to assess the safety and efficacy of MSCs for the treatment of SNHL. The objective of the proposed systematic review is to examine the efficacy of MSCs as a therapy for SNHL in animal models. Methods: We will include preclinical animal studies of SNHL in which MSCs are administered, and outcomes are compared against MSC-naïve controls. The primary outcome will include audiologic tests that are routinely used in experimental studies of hearing loss, such as auditory brainstem response (ABR) and distortion product otoacoustic emissions testing (DPOAE). Secondary outcomes will include histology, microscopy, gene protein expression, and behavioral responses of animals. Electronic searches of MEDLINE via PubMed, Scopus, ScienceDirect, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be performed. Search results will be screened independently and in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias and publication bias will be assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool and Funnel Plots/Egger's regression tests, respectively. Discussion: This systematic review will provide a summary of the efficacy of MSC therapy in animal models of SNHL, utilizing functional hearing assessment as a primary outcome. Findings from this review are important because they can elucidate research gaps that should be addressed in future preclinical studies and in turn can be translated into clinical studies.

AB - Background: Sensorineural hearing loss (SNHL) is the most common form of hearing impairment and is characterized by a loss of receptor hair cells and/or spiral ganglion neurons. Regenerative stem cell therapy could potentially restore normal hearing and slow the progression of hearing loss in patients. Preclinical animal studies have demonstrated that mesenchymal stem cells (MSCs) could be a promising new therapy for this condition. These findings have prompted investigators to begin human clinical trials to assess the safety and efficacy of MSCs for the treatment of SNHL. The objective of the proposed systematic review is to examine the efficacy of MSCs as a therapy for SNHL in animal models. Methods: We will include preclinical animal studies of SNHL in which MSCs are administered, and outcomes are compared against MSC-naïve controls. The primary outcome will include audiologic tests that are routinely used in experimental studies of hearing loss, such as auditory brainstem response (ABR) and distortion product otoacoustic emissions testing (DPOAE). Secondary outcomes will include histology, microscopy, gene protein expression, and behavioral responses of animals. Electronic searches of MEDLINE via PubMed, Scopus, ScienceDirect, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be performed. Search results will be screened independently and in duplicate. Data from eligible studies will be extracted, pooled, and analyzed using random effects models. Risk of bias and publication bias will be assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool and Funnel Plots/Egger's regression tests, respectively. Discussion: This systematic review will provide a summary of the efficacy of MSC therapy in animal models of SNHL, utilizing functional hearing assessment as a primary outcome. Findings from this review are important because they can elucidate research gaps that should be addressed in future preclinical studies and in turn can be translated into clinical studies.

KW - Animal models

KW - Mesenchymal stem cells

KW - Preclinical

KW - Risk of bias

KW - Sensorineural hearing loss

KW - Stem cells

KW - Systematic reviews

UR - http://www.scopus.com/inward/record.url?scp=85066406385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066406385&partnerID=8YFLogxK

U2 - 10.1186/s13643-019-1015-7

DO - 10.1186/s13643-019-1015-7

M3 - Review article

C2 - 31128597

AN - SCOPUS:85066406385

VL - 8

JO - Systematic Reviews

JF - Systematic Reviews

SN - 2046-4053

IS - 1

M1 - 126

ER -